<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04836611</url>
  </required_header>
  <id_info>
    <org_study_id>CANEMESE</org_study_id>
    <nct_id>NCT04836611</nct_id>
  </id_info>
  <brief_title>Cannabinoides Concentrations and Hyperemesis Syndrom Occurrence in Regular Cannabis Consumer (CANEMESE)</brief_title>
  <official_title>Cannabinoides Concentrations and Hyperemesis Syndrom Occurrence in Regular Cannabis Consumer (CANEMESE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Cannabinoide Hyperemesis Syndrom (CHS) is defined as a recurrent syndrome of intractable&#xD;
      vomiting that occurs in chronic cannabis consumers. The diagnosis is linked to clinical&#xD;
      criteria only. The physiopathology of CHS is unknown and we observe an increase of cases with&#xD;
      this syndrom since 2016 (Schreck et al., 2018).&#xD;
&#xD;
      The aim of this study is to investigate the involvement of exogenous cannabinoids&#xD;
      concentrations in chronic cannabis users in the occurrence of CHS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>involvement of exogenous cannabinoids concentrations in chronic cannabis users in the occurrence of CHS (see details below for exogenous cannabinoids)</measure>
    <time_frame>on the day of subjects inclusion</time_frame>
    <description>blood and urine concentration, unit of measure ng/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>THC (Tetrahydrocannabinol)</measure>
    <time_frame>on the day of subjects inclusion</time_frame>
    <description>blood and urine concentration, unit of measure ng/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>metabolite of THC : THC-OH (11-hydroxy-Δ⁹-tétrahydrocannabinol)</measure>
    <time_frame>on the day of subjects inclusion</time_frame>
    <description>blood and urine concentration, unit of measure ng/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>metabolite of THC : THC-COOH (11-nor-9-carboxy-Δ⁹-tétrahydrocannabinol)</measure>
    <time_frame>on the day of subjects inclusion</time_frame>
    <description>blood and urine concentration, unit of measure ng/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CBD (Cannabidiol)</measure>
    <time_frame>on the day of subjects inclusion</time_frame>
    <description>blood and urine concentration, unit of measure ng/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CBN (Cannabinol)</measure>
    <time_frame>on the day of subjects inclusion</time_frame>
    <description>blood and urine concentration, unit of measure ng/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CBG (Cannabigerol)</measure>
    <time_frame>on the day of subjects inclusion</time_frame>
    <description>blood and urine concentration, unit of measure ng/mL</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Chronic Consumption of Cannabis</condition>
  <arm_group>
    <arm_group_label>regular cannabis consumer patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>1 blood sample</intervention_name>
    <description>2 groups of subjects (group 1 : with diagnosis of CHS - group 2 : no diagnosis of CHS) will have 2 blood and 1 urine samples + 1 questionnaire</description>
    <arm_group_label>regular cannabis consumer patients</arm_group_label>
    <other_name>1 urine sample</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects without protection by a legal regime (guardianship, trusteeship)&#xD;
&#xD;
          -  Subjects affiliated to an appropriate social security system&#xD;
&#xD;
          -  Subjects must sign an informed consent form&#xD;
&#xD;
        Inclusion Criteria for Group 1:&#xD;
&#xD;
        - Subjects must have the CHS diagnosis confirmed&#xD;
&#xD;
        Inclusion Criteria for Group 2:&#xD;
&#xD;
        - Subjects must be chronic cannabis consumers and never had CHS&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects must not have addictive comorbidities or psychoactive substance abuse (except&#xD;
             alcohol and tabacco)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GUENEZAN Jérémy, MD</last_name>
      <phone>+33(0)549444444</phone>
      <email>jeremy.guenezan@chu-poitiers.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

